HLA-C Expression Pattern Is Spatially Different Between Psoriasis and Eczema Skin Lesions
HLA-C Expression Pattern Is Spatially Different Between Psoriasis and Eczema Skin Lesions
HLA-C Expression Pattern Is Spatially Different Between Psoriasis and Eczema Skin Lesions
INTRODUCTION
Association between psoriasis and the major histocompatibility complex (MHC) region is firmly established (McMichael et al., 1978; Laurentaci et al., 1982; Henseler and
Christophers, 1985). A minimal genomic segment defining
the psoriasis susceptibility locus 1 (PSORS1) on chromosome
6 (Jenisch et al., 1998; Balendran et al., 1999; Oka et al.,
1999; Nair et al., 2000) contains a number of proposed
candidate genes, for example HLA-C, CDSN (corneodesmosin), CCHCR1 (coiled-coil alpha-helical rod protein 1), SEEK,
and PSORS1C3 (Bowcock and Krueger, 2005). All of them
have been investigated for strength of association to psoriasis
in genetic studies but only some have been studied for
expression in skin (Holm et al., 2003; Suomela et al., 2003;
Capon et al., 2004). There are no published studies that
describe HLA-C expression in psoriasis despite the fact that its
association to disease has been known for several decades.
It is known that under non-inflammatory conditions all
nucleated cells express class I molecules, and that one of
their important functions is to suppress self-reactivity by
engaging inhibitory receptors on natural killer (NK), NK-T
and CD8 cells (Martin and Carrington, 2005; Rajagopalan
1
342
L Carlen et al.
HLA-C Expression Pattern in Psoriasis
Figure 1. HLA-C expression detected by immunohistochemistry with mAb L31. (a) Tonsil, (b) adult colon epithelium, (c) fetal colon epithelium, (d) normal
skin, (e) plaque psoriasis, (f) allergic contact eczema (original magnification 20, Bar 100 mM, insets: 100, Bar 20 mm) (g) LCL721.221 cells expressing
HLA-Cw3 before lipopolysaccharide stimulation, and after (h) 16, (i) 48, and (j) 96 hours post-stimulation (original magnification 40, Bar 50 mm).
www.jidonline.org
343
L Carlen et al.
HLA-C Expression Pattern in Psoriasis
a
Expressiom index
1.0
0.6
0.4
0.2
LE
LG
LP
N
NLE
Phenotype
NLG
NLP
LE
LG
LP
N
NLE
Phenotype
NLG
NLP
0.5
Expressiom index
0.8
0.4
0.3
0.2
0.1
0.0
45 kDa
b
C NLG LE
LG
LP NLE LP
L Carlen et al.
HLA-C Expression Pattern in Psoriasis
345
L Carlen et al.
HLA-C Expression Pattern in Psoriasis
Antibodies
The following antibodies were used: (1) Murine mAb L31 which
binds linear a1 domain epitope at position 67 of human HLA-C
alleles Cw1 through Cw8 and HLA-B8 and B51 (Setini et al., 1996).
Alleles from Cw9 to Cw17, and B8 and B51 do not associate with
psoriasis, therefore, under-or overestimation of expression levels is
expected to cancel out between patients and controls. (2) Murine
mAb W6/32 (Serotec, Oxford, UK) (Brodsky et al., 1979) which
binds MHC class I heavy chain associated with b-2-microglobulin.
(3) Murine mAb MCA2243 (NKVFS1) (Serotec) (Spaggiari et al.,
2002) which recognizes a common epitope on CD158a and
CD158b (KIR2DL1, KIR2DL2), and (4) horse radish peroxidaseconjugated rabbit polyclonal P0174 (DakoCytomation, Glostrup,
Denmark) which binds human b2m. As secondary antibody, horse
radish peroxidase-conjugated goat anti-mouse IgG (Santa Cruz,
sc-2005) was used.
Sample preparation
Skin biopsies were prepared as described previously (Carlen et al.,
2005). In brief, the biopsies were kept frozen in liquid nitrogen and
mechanically homogenized using a mortar and pestle. The samples
were then solubilized in a buffer containing 7 M urea, 2 M thiourea,
4% SDS, reducing agents, and protease inhibitors. Protein concentration was determined using the Bradford method (BioRad Protein
Assay, BioRad, Stockholm, Sweden) (Bradford, 1976).
Western blot
Total protein extracts were separated, adding 7 mg of each sample to
12% SDS-PAGE gels, and then electroblotted onto nitrocellulose
membranes (Whatman Schleicher & Schuell, Kent, UK). The
membranes were then stained with 1% Ponceau S (Sigma, St Louis,
MO) and scanned to check for loading and gel run quality. After
blocking with 2% goat serum (Vector Laboratories, Burlingame, CA)
and 1% BSA (Sigma, St Louis, MO) in Tris-buffered saline for 1 hour,
the membranes were incubated separately overnight with L31, W6/
32, MCA2243, or b2m antibody diluted 1:500 in TBS with 1%
Tween 20. The membranes were then incubated with horse radish
346
peroxidase-conjugated goat anti-mouse IgG (Santa Cruz Biotechnology, Santa Cruz, CA) (except for b2m) diluted 1:2,000 in blocking
buffer followed by development using enhanced chemiluminescence (Amersham Pharmacia Biotech, Sunnyvale, CA) and the
image acquired with a CCD camera (Fujifilm, Sendai, Japan). The
immunoreactivity of the HLA-C and b2m antibodies was tested
against recombinant HLA-C and b2-microglobulin. Unspecific
binding of the secondary antibody was prevented by pre-incubation
in normal goat serum.
Immunohistochemistry
All biopsies were snap-frozen and stored at 701C until further
processed. Skin samples from lesional and non-lesional eczema and
plaque and guttate psoriasis, and healthy skin were included in the
same experiments. In short, 67-mm thick cryostat sections were
incubated with L31, W6/32, and MCA2243 antibody at 1:200,
1:20,000, and 1:200 dilutions, respectively. All sections were
stained using the avidin: biotinylated enzyme complex technique
(Vector Laboratories, Burlingame, CA) following the manufacturers
instructions, and counterstained with Gills III hematoxylin solution.
As controls, tissue sections were processed in parallel without
adding primary antibody. No reactivity for secondary antibodies or
signal developing reagents was observed on control histological
sections.
Cell culture
LCL721.221 cells were maintained in DMEM (Gibco-BRL Life
Technologies, Paisley, UK) supplemented with 10% FCS (fetal calf
serum; Hy-Clone, Boule Nordic AB Huddinge, Sweden) and
antibiotics (PEST _ penicillin 50 U/l and streptomycin 50 mg/ml;
Gibco-BRL) at 5% CO2 at 371C. HLA-Cw3 and Cw4 transfectants
were kept under G418 (GibcoBRL) selection. During stimulation
experiments, about 105 cells/well were grown in 12-well plates
without selection with G418 for 2 days and then exposed to 1 mg/ml
E. coli-derived lipopolysaccharide. HLA-C expression was detected
with the L31 antibody at time 0 and 16, 48 and 96 hours after
stimulation. The cells were then transferred to slides, fixed with
ethanol, and further processed as described in the immunohistochemistry section above.
Data analysis
Image analysis was carried out using Science Lab 99 L Process
software, version 1.95 (Fujifilm, Sendai, Japan). Intensity measurements of specific signals were corrected by the total amount of
protein in their corresponding lanes as derived from measurement of
Ponceau staining intensities of the membranes. Variations in
luminosity between images were adjusted by using an HLA-Cpositive cell line as internal control on every membrane and
the density values were adjusted using the following formulae:
Expression Index (corrected sample reading)/(corrected Ponceau
reading).
Corrected sample reading (sample density (Strongest intergel
control/samples gel control))
Corrected Ponceau reading reading of control lane/sum of
readings from all lanes in gel
Statistical analysis was performed using the R language and
statistics package (Ihaka and Gentleman, 1996). Mean expression
indexes from different sample groups were compared by fitting a
L Carlen et al.
HLA-C Expression Pattern in Psoriasis
ACKNOWLEDGMENTS
We thank Dr Eniko Sonkoly for critically reviewing this manuscript, AnnaLena Kastman for skilful technical assistance with immunohistochemistry,
Dr Gunther Weber for providing HLA-C-positive cell lines and for assistance
with immunoblotting, Dr Alberto Beretta for providing us with the L31
HLA-C antibody, Dr Jack Strominger, and Dr Hugh Reyburn for providing
HLA-C constructs, and Dr Kalle Malmberg and Dr Hans Gustav Ljunggren for
HLA-C transfected LCLs. This study was supported by funds from the
Swedish Research Council, the Swedish Heart and Lung Foundation, the
Swedish Psoriasis Association, Ake-Wibergs foundation, Serono, Biogen,
Schering-Plough, the National Psoriasis Foundation, Karolinska University
Hospital, and Karolinska Institutet.
REFERENCES
Baba E, Erskine R, Boyson JE, Cohen GB, Davis DM, Malik P et al. (2000)
N-linked carbohydrate on human leukocyte antigen-C and recognition by natural killer cell inhibitory receptors. Hum Immunol 61:
120218
Balendran N, Clough RL, Arguello JR, Barber R, Veal C, Jones AB et al. (1999)
Characterization of the major susceptibility region for psoriasis at
chromosome 6p21.3. J Invest Dermatol 113:3228
Bowcock AM (2005) The genetics of psoriasis and autoimmunity. Annu Rev
Genomics Hum Genet 6:93122
Bowcock AM, Krueger JG (2005) Getting under the skin: the immunogenetics
of psoriasis. Nat Rev Immunol 5:699711
Boyington JC, Brooks AG, Sun PD (2001) Structure of killer cell immunoglobulin-like receptors and their recognition of the class I MHC molecules.
Immunol Rev 181:6678
www.jidonline.org
347
L Carlen et al.
HLA-C Expression Pattern in Psoriasis
348
Zhou X, Krueger JG, Kao MC, Lee E, Du F, Menter A et al. (2003) Novel
mechanisms of T-cell and dendritic cell activation revealed by profiling
of psoriasis on the 63,100-element oligonucleotide array. Physiol
Genomics 13:6978
Petersdorf EW, Longton GM, Anasetti C, Mickelson EM, McKinney SK, Smith
AG et al. (1997) Association of HLA-C disparity with graft failure after
marrow transplantation from unrelated donors. Blood 89:181823